Journal of investigative medicine : the official publication of the American Federation for Clinical Research
-
The aim of this study was to investigate the association between fine particulate matter 2.5 (PM2.5) and oral cancer among Taiwanese men. Four linked data sources including the Taiwan Cancer Registry, Adult Preventive Medical Services Database, National Health Insurance Research Database, and Air Quality Monitoring Database were used. ⋯ Logistic regression was used to examine the association between PM2.5 and oral cancer diagnosed from 2012 to 2013. After adjusting for potential confounders, the ORs of oral cancer were 0.91 (95% CI 0.75 to 1.11) for 26.74≤PM2.5<32.37, 1.01 (95% CI 0.84 to 1.20) for 32.37≤PM2.5<40.37 µg/m3 and 1.43 (95% CI 1.17 to 1.74) for PM2.5≥40.37 µg/m3 compared with PM2.5<26.74 µg/m3 In this study, there was an increased risk of oral cancer among Taiwanese men who were exposed to higher concentrations of PM2.5.
-
Multiple myeloma (MM) is characterized by the proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraproteins (M proteins). Everolimus works similarly to sirolimus as a mammalian target of rapamycin (mTOR) inhibitor. Bortezomib was the first therapeutic proteasome inhibitor to be tested in humans with MM. ⋯ In this study, we compared the therapeutic effects of everolimus and bortezomib, as well as those of a combination of everolimus and bortezomib, using an in vitro MM cell line model and in vivo xenograft mouse model. Our results showed that the synergistic antitumor effects of everolimus and bortezomib have significant inhibitory effect through inhibition of the AKT/mTOR pathway in both the MM cell lines and MM-bearing mice model. Our results provided evidence that the mTOR inhibitor, everolimus, will be a potential drug in MM therapy.